PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
57.79%
Revenue growth above 1.5x CVE's 6.68%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
142.67%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
1020.37%
Positive EBIT growth while CVE is negative. John Neff might see a substantial edge in operational management.
1020.37%
Positive operating income growth while CVE is negative. John Neff might view this as a competitive edge in operations.
253.38%
Net income growth above 1.5x CVE's 131.87%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
234.15%
EPS growth above 1.5x CVE's 127.27%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
234.15%
Diluted EPS growth above 1.5x CVE's 127.27%. David Dodd would see if there's a robust moat protecting these shareholder gains.
13.36%
Share change of 13.36% while CVE is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
13.36%
Diluted share change of 13.36% while CVE is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-5.49%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-46.73%
Negative OCF growth while CVE is at 100.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-90.26%
Negative FCF growth while CVE is at 115.79%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-76.60%
Negative 10Y revenue/share CAGR while CVE stands at 29.76%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-45.44%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-47.79%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-94.94%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-87.00%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-91.44%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-20.96%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
2617.93%
Positive 5Y CAGR while CVE is negative. John Neff might view this as a strong mid-term relative advantage.
182.96%
Positive short-term CAGR while CVE is negative. John Neff would see a clear advantage in near-term profit trajectory.
-64.84%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-41.72%
Negative 5Y equity/share growth while CVE is at 9.45%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-5.06%
Negative 3Y equity/share growth while CVE is at 5.31%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-91.06%
Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-92.28%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-77.60%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
77.76%
AR growth well above CVE's 6.00%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
0.29%
Positive asset growth while CVE is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-6.04%
We have a declining book value while CVE shows 1.10%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-1.10%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
2.27%
We expand SG&A while CVE cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.